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Background: Rituximab, a monoclonal antibody that selectively targets CD20-positive 
B-lymphocytes, is used for the treatment of patients with rheumatoid arthritis (RA) with an 
inadequate response or tolerance to tumor necrosis factor inhibitors. The objective of this study 
was to investigate the effects of rituximab treatment on the serum concentrations of vitamin D, 
interleukin (IL) 2, IL-6, IL-7, and IL-10 in patients with rheumatoid arthritis (RA).
Methods: Forty-five patients, aged 25–78 years, were enrolled into a cohort prospective study. 
All patients were treated with intravenous rituximab. Disease activity score-28 (DAS-28) and 
serum concentrations of rheumatoid factor (RF), C-reactive protein (CRP), anticyclic citrullinated 
peptide (anti-CCP), erythrocyte sedimentation rate (ESR), health assessment questionnaire 
(HAQ), vitamin D, ILs 2, 6, 7, and 10 were estimated in the patients before and after treatment 
with rituximab.
Results: DAS-28, HAQ score, and serum concentrations of CRP, RF, anti-CCP, IL-2, IL-6, 
IL-7, IL-10, and ESR significantly decreased after treatment. All 45 patients had vitamin D 
deficiency before treatment and this did not significantly change after treatment. However no 
significant association was found among serum vitamin D concentration and any of the ILs.
Conclusion: We concluded from this study that although rituximab treatment of patients with 
RA significantly reduced their disease activity and serum concentrations of IL-2, IL-6, IL-7, and 
IL-10, it did not significantly alter their vitamin D status. Furthermore, no significant association 
was found among serum vitamin D concentration and any of the ILs.
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Introduction
Vitamin D, or cholecalciferol, is a steroidal hormone whose main function is the 
regulation of calcium homeostasis and bone formation and reabsorption.1 Recently, 
there has been a plethora of data on the noncalcitropic effects of vitamin D deficiency, 
separate from its known associations with increased fracture risk.2,3 As an example, 
vitamin D has been shown to alter the expression of more than 200 genes that affect 
cellular functions such as proliferation, differentiation, apoptosis, and angiogenesis.4 
Thus vitamin D deficiency has been associated with various cancers.5–8
There is also a growing body of evidence that vitamin D is important in the 
initiation and propagation of a range of autoimmune diseases.9–11 This vitamin inhibits 
antibody secretion and autoantibody production in B cells.12 It has also been reported 
that synovium and lymphocytes from patients with rheumatoid arthritis (RA) express 
vitamin D receptor. The metabolically active form of the vitamin 1, 25 dihydroxyvitamin 
D3 (1, 25-OHD) inhibits T-cell proliferation and prevents the release of  Th-1 cytokines 
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such as interleukin (IL)-2, interferon-γ and tumor necrosis 
factor (TNF)-α.13
Thus, some but not all studies, have implicated low 
vitamin D intake as a risk factor in the development of RA. 
There are reports linking low vitamin D levels with increased 
disease activity and severity in patients with inflammatory 
arthritis.14–18 A number of studies have also demonstrated an 
inverse association between vitamin D and disease activity in 
patients with inflammatory arthritis but the results of these 
studies were not similar.19–21
Rituximab is a monoclonal antibody that selectively 
targets CD20-positive B lymphocytes.22 It is approved for the 
treatment of patients with RA with an inadequate response 
or tolerance to TNF inhibitors. The drug has been reported to 
provide significant and clinically meaningful improvements 
in disease activity in patients with longstanding RA who had 
been resistant to one or more anti-TNF therapies.22 Rituximab 
also inhibits the progression of structural damage in RA 
patients.23 Since this drug is a B-cell depleter, its use offers 
an opportunity to study the relationship between vitamin D 
status and some cytokines. The objectives of this study were 
therefore (1) to study the effect of rituximab treatment on 
vitamin D status in patients with RA and (2) to find out if 
there are any significant associations among serum vitamin 
D concentrations and proinflammatory cytokines (IL-2, IL-6, 
and IL-7) and anti-inflammatory cytokines (IL-10) to justify 
the acclaimed link of vitamin D to cytokine production.
Patients and methods
Study patients
Consecutive patients attending the Rheumatology Outpatient 
Clinic of Al-Amiri Teaching Hospital, Kuwait, who fulfilled 
the American College of Rheumatology (formerly the 
American Rheumatism Association) 1987 revised criteria24 
were recruited for this study.
All patients first received one course of intravenous 
(IV) rituximab 1000 mg and a second IV infusion of 
1000 mg 2 weeks later after IV methylpredinosolone 
100 mg premedication. There was a washout period of at 
least 3 months before giving rituximab to those who had 
been on TNF-α blockers. All the patients were assessed 
before rituximab treatment and 6 months after the second 
dose of rituximab. The assessment consisted of counting 
the number of tender and swollen joints, estimation of 
the erythrocyte sedimentation rate (ESR) by the Wester-
gren method, measurement of serum concentrations of 
C-reactive protein (CRP) by the nephelometric method, 
and evaluation of disease activity by the Disease Activity 
for 28 Joint Indices Score (DAS-28).25 Functional disability 
was measured by using the Arabic version of the Health 
Assessment Questionnaire (HAQ).26 All patients gave 
written informed consents and the study protocol was 
approved by the local ethics committee.
Measurement of serum 25-OH-D 
concentrations
Banked serum samples collected from the patients before and 
after treatment with rituximab were analyzed for 25-OH-D3 
using the commercially available Immunodiagnostic Systems 
RIA kit (Immunodiagnostic Systems Ltd, Boldon Tyne and 
Wear, UK). This kit is a liquid phase radioimmunoassay 
kit for the quantitation of 25-hydroxy vitamin D and other 
hydroxylated metabolites in human serum or plasma. The 
sensitivity of the assay in our laboratory is ,3 nmol/L while 
the intra assay and inter assay coefficient of variations were 
5.0 and 8.1%, respectively. Insufficiency of 25-OH-D 
was defined as ,70 nmol/L (,30 ng/mL) and deficiency 
as ,50 nmol/L (,20 ng/mL). The normal range in our 
laboratory is 70–100 nmol/L.
Measurement of serum iL-2, iL-6, iL-7, 
and iL-10 concentrations
The serum concentrations of these ILs in patients with 
RA before and after treatment with rituximab were 
estimated by using commercially available ELISA kits from 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
32
Hasan et al
Table 1 Demographic and clinical characteristics of patients with 
active RA before treatment with rituximab
Characteristics n = 45
Gender ratio (M:F) 1.1:3.4
Age (years) 
  Mean ± SD 
  Range
 
48.9 ± 1.78 
(25–78)
Age at onset (years) 
  Mean ± SD 
  Range
 
36.6 ±11.4 
(14–70)
RA duration (months) 
  Median (interquartile) 
  Range
 
120 
(6–336)
Treatment 
  Prednisolone (%) 
  DMARDs (%) 
  One 
  $2 
Previous anti-TnF (%) 
  1 anti-TnF 
  2 anti-TnFs 
  3 anti-TnFs
 
20.7 
 
62.1 
13.8 
 
41.3 
26.1 
6.5
Abbreviations: RA, rheumatoid arthritis; M, male; F, Female; SD, standard deviation; 
DMARDs, disease modifying anti-rheumatic drugs; TnF, tumor necrosis factor.Biologics: Targets and Therapy 2012:6
after treatment with rituximab. All patients, before and after 
treatment, had serum vitamin D concentrations of less than 
50 nmol/L, the deficiency value in our laboratory. We did 
not include controls in this study because our aim was not to 
compare the prevalences of vitamin D deficiencies between 
patients with RA and the healthy population but to demon-
strate the effect of rituximab treatment on vitamin D status. 
Figure 1 also shows that rituximab treatment did not signifi-
cantly alter the status of vitamin D in patients with RA.
Table 3 shows that the mean serum concentrations of 
IL-2, IL-6, IL-7, and IL-10 significantly fell in patients with 
RA following treatment with rituximab. For example, serum 
IL-2 concentration fell from 52.56 ± 6.29 pg/mL before treat-
ment to 8.77 ± 1.81 pg/mL after treatment while IL-7 fell 
from 146.63 ± 9.23 pg/mL before treatment to 68.71 ± 11.63 
pg/mL after treatment.
Association among serum vitamin D 
concentration and serum iLs before  
and after treatment with rituximab
Table 4 shows that there were no significant associations 
among serum vitamin D concentration and serum IL-2, 
Rituximab 
posttreatment
Rituximab 
pretreatment
20.00
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50.00
15.35 ± 1.09 16.75 ± 1.2
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Figure 1 Scatter plot of vitamin D in patients with rheumatoid arthritis before and 
after treatment with rituximab.
IMMUNOTECH SAS (Marsielle, France).  The instructions 
of the manufacturer of the kits were followed.
Statistical analysis
Data were analyzed using the Statistical Package for Social 
Sciences Software ([SPSS] v17.0; SPSS Inc, Chicago, IL). 
The variables were examined for normality with the Kolm-
ogorov-Smirnov test, and descriptive statistics presented as 
appropriate. The differences between pretreatment and post-
treatment values were compared using nonparametric Mann–
Whitney or Kruskal–Wallis tests. Vitamin D concentrations 
were tested for any relationship with IL concentrations using 
Spearman correlation coefficient. The two-tailed probability 
P , 0.05 was considered statistically significant.
Results
Demographic characteristics
A total of 45 patients with active RA were enrolled into the 
study. Of these, 34 (75.6%) were females and 11 (24.4%) 
were males (Table 1). The mean age of the patients was 
48.9 ± 1.78 years with a range of 25–78 years. The mean age 
at disease onset was 36.6 ± 11.4 years ranging from 14–70 
years. The median RA duration was 10 years ranging from 
6 months to 28 years. None of the patients had any significant 
dietary change that might affect vitamin D intake during the 
study. None of the patients had abnormal liver or renal func-
tions that might affect the serum vitamin D concentrations.
Clinical and laboratory parameters
Table 2 shows a significant decrease in DAS-28, HAQ, serum 
concentrations of RF, CRP, anti-CCP, and ESR following 
treatment of RA patients with rituximab, suggesting that 
the drug was effective in reducing the inflammation of RA.
Serum concentrations of vitamin D, iL-2, 
iL-6, iL-7, and iL-10
Figure 1 is a scatter plot showing the distribution of serum 
vitamin D concentrations in patients with RA before and 
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Table 2 Clinical and laboratory parameters in patients with RA before and after treatment with rituximab
Parameter Before treatment After treatment P value
DAS-28   6.28 ± 0.24   3.84 ± 0.30 0.001
HAQ   2.89 ± 0.83   1.52 ± 0.61 0.05
Mean serum RF 721.84 ± 51.5   93.32 ± 30.3 0.001
Mean ESR (mm/hr)   35.5 ± 5.21      18 ± 6.35 0.001
Mean serum CRP (mg/dL)   27.21 ± 3.76   11.54 ± 1.92 0.001
Mean serum anti-CCP (U/mL) 563.34 ± 93.64 350.75 ± 113.25 0.001
Abbreviations: RA, rheumatoid arthritis; DAS, disease activity score; HAQ, health assessment questionnaire; RF, rheumatoid factor; ESR, erythrocyte sedimentation rate; 
CRP, C-reactive protein; anti-CCP, anti-cyclic citrullinated peptide.Biologics: Targets and Therapy 2012:6
IL-6, IL-7, and IL-10 in patients with RA before and after 
treatment with rituximab.
Discussion
Although our objectives in this study did not include the 
investigation of the prevalence of vitamin D deficiency in 
patients with RA (and this was why we did not include any 
healthy controls), it is important to note that all 45 patients 
with RA had vitamin D deficiency before treatment. This 
finding is in accord with the almost pandemic vitamin D 
hypovitaminosis reported all over the world in general26,27 
and in patients with RA in particular.28–30
The second important result from this study was that 
treatment of RA patients with rituximab did not alter their 
vitamin D status. To the best of our knowledge, this is the 
first report of the effect of rituximab treatment on serum 
vitamin D concentrations in patients with RA. It was sur-
prising that rituximab did not affect vitamin D status since 
vitamin D has been reported to inhibit antibody secretion 
and T cell proliferation.12,13 Rituximab is known to deplete 
B cells that produce antibodies. Therefore one would have 
expected that rituximab treatment would cause a significant 
reduction in serum vitamin D concentration. Why this was 
not so is not clear but further investigations on the relation-
ship between vitamin D, antibody production by B cells, and 
cytokine serum concentrations need to be carried out on a 
large population.
The third important result of this study was that rituximab 
treatment of patients with RA significantly reduced their disease 
activity and their serum concentrations of RF, CRP, anti-CCP, 
and ESR. In this study, we found significant reductions in the 
serum concentrations of proinflammatory interleukins such as 
IL-2, IL-6, and IL-7. The reduction in disease activity in RA 
after treatment with rituximab might be due to the reductions 
in these proinflammatory ILs. It was surprising to find that 
treatment with rituximab in patients with RA also reduced 
their serum concentrations of IL-10, an anti-inflammatory 
IL. This might be due to the fact that rituximab depletes all 
B lymphocytes. The long term effect of this reduction in 
patients treated with rituximab is not known.
Perhaps the most important finding in this study was that 
the serum concentration of vitamin D was not significantly 
associated with serum concentration of either IL-2, IL-6, 
IL-7, or IL-10. These findings contradict the reports that 
vitamin D downregulates the production of several cytokines 
such as IL-2, IL-6, IL-12, interferon-γ, TNF-α, and TNF-β in 
in vitro studies.31,32 Our results, however, were in   agreement 
with those of Vilarrasa et al33 who recently reported that 
no significant associations were found amongst 25-OHD 
and plasma concentrations of IL-18 and other cytokines. 
  Further studies on larger sample sizes of healthy   populations 
are needed to investigate the associations among serum 
  vitamin D and IL concentrations.
Conclusion
We discovered from our study that treatment of RA patients 
with rituximab did not significantly alter their already 
depleted vitamin D status, although it significantly reduced 
their indices of inflammation and their serum concentrations 
of IL-2, IL-6, IL-7, and IL-10.
Disclosure
The authors report no conflicts of interest in this work.
Table 3 Serum concentrations of vitamin D, iL-2, iL-6, iL-7, and iL-10 in patients with RA before and after treatment with rituximab
Analyte Before treatment  
(mean ± SD)
After treatment  
(mean ± SD)
P value
Serum vitamin D (nmol/L)   15.35 ± 1.09 16.75 ± 1.2 0.39
Serum iL-2 (pg/mL)   52.56 ± 6.29   8.77 ± 1.81 0.0001
Serum iL-6 (pg/mL)   34.56 ± 5.01 21.32 ± 2.99 0.01
Serum iL-7 (pg/mL) 146.63 ± 9.23 68.71 ± 11.63 0.001
Serum iL-10 (pg/mL)   32.26 ± 6.01 17.21 ± 2.84 0.01
Abbreviations: iL, interleukin; RA, rheumatoid artritis; SD, standard deviation.
Table 4 Association among serum vitamin D concentration and 
serum iLs in patients with RA before treatment with rituximab
Serum ILs Associations with  
serum vitamin D
Comments
iL-2 r = 0.05 
P = 0.75
No significant association
iL-6 r = 0.036 
P = 0.82
No significant association
iL-7 r = -0.003 
P = 0.98
No significant association
iL-10 r = -0.03 
P = 0.85
No significant association
Abbreviations: iL, interleukin; RA, rheumatoid arthritis.
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